(Documents VI and VII)

(a) Social consequences: There is no evidence specifically on MBDB. The available evidence
on MDMA does not show any major harmful social consequences for users arising directly
from its use, in terms of family or other social relations, problems concerning education,
employment or marginalisation. On the basis of comparison with MDMA, and given that MBDB
constitutes a small proportion of the much broader ecstasy market, it is very unlikely that there
are any significant harmful social consequences for the user that could be attributed
specifically to the use of MBDB.

(b) Consequences for the social behaviour of the user: There is no evidence specifically on
MBDB and consequences linked to disorderly conduct, acquisitive crime or violence.
However, it might be considered even more unlikely than with MDMA that there is any
important link between the use of MBDB and such consequences. The effect on driving is
unknown but, as with any drug, is a matter of concern.

(c ) Other social consequences: There is no indication that MBDB in particular is associated
with any major value conflicts or has any important implications for social institutions beyond
those described for MDMA.

(d) Wholesale manufacture and distribution: The Europol contribution confirms the information
collected by the Reitox National Focal Points about the current level of small-scale distribution
and trafficking of MBDB when compared with other synthetic drugs. Seizures in the European
Union have been limited, both in number and quantity, compared with the total number of
seized ecstasy tablets. Information from law-enforcement agencies in the Member States has
not revealed whether criminal groups specifically manufacture MBDB with a view to avoiding
legal controls. Some Member States have indicated the involvement of organised crime in the
large-scale manufacture of and trafficking in MBDB.